Business Context and Reporting Period
This Form 8-K was filed by OvaScience, Inc. (noted as Tempest Therapeutics in metadata) on January 9, 2017. The filing serves as a Regulation FD disclosure regarding an upcoming corporate presentation at the 35th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational milestones and forward-looking statements rather than financial performance data.
Material Changes and Operational Milestones
The company outlined updated corporate goals for its bovine and human EggPC cell-derived treatments. Key milestones include:
- Bovine Program: Fertilize bovine EggPC cell-derived oocyte by end of 2017; perform embryo transfer by Q1 2018; achieve live birth by Q1 2019; obtain six-month follow-up data by Q3 2019.
- Human Program (Research): Mature human EggPC cell-derived egg by Q2 2018; receive authorization to fertilize human cells by Q2 2018.
- OvaTure: Submit for regulatory approval (clinical study) by Q2 2019.
- OvaPrime Clinical Study (Canada): Complete enrollment of 70 patients by Q2 2017; complete biopsies by Q4 2017; complete reintroduction by H1 2018; present initial safety readout for 20 patients by end of 2017.
Guidance, Risks, and Contingencies
Management emphasized that the stated goals are forward-looking statements and actual results may differ materially. Significant risks identified include:
- Unproven science underlying the AUGMENT, OvaPrime, and OvaTure treatments.
- Regulatory risks regarding authorization to fertilize human EggPC cells.
- Dependence on international IVF partners who may limit or delay treatments based on efficacy, safety, or commercial reasons.
- Challenges in enrolling and completing clinical trials.
- Scientific challenges in characterizing and fertilizing EggPC cell-derived eggs.
The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the company's current cash runway given the lack of revenue data and high R&D burn rate implied by the clinical timeline.
- Confirm the status of regulatory approvals required for human EggPC cell fertilization.
- Monitor the enrollment progress of the OvaPrime study in Canada against the Q2 2017 target.
- Review the "Risk Factors" section of the most recent Form 10-Q or 10-K for detailed disclosures on scientific and commercial risks.
- Assess the reliability of the bovine-to-human translation timeline given the unproven nature of the underlying science.